



Kroger
Prescription
Plans

Biosimilar Newsletter

Market Analysis

Biosimilars are FDA approved medications that are expected to produce the same clinical results as safely and effectively as the biologic medicine that the biosimilar is comparable to, referred to as the "reference product." The biosimilar market in the U.S. is growing, with a total of 39 biosimilars FDA approved at the time of this publication. With the growing trend of specialty drugs being used to treat complex chronic conditions, there's an opportunity for biosimilars to enter the market as alternative therapeutic options at lower prices.

KPP offers unique management for biosimilars to include engagement with medical benefit providers, collaboration at our pharmacies, and advocating for a low net-cost strategy. In October 2023, KPP added select adalimumab biosimilars to the formulary as additional options for members. The formulary strategy will continue to be evaluated in 2024 and beyond with the anticipation of biosimilar products to Stelara, Actemra, and many others. As always, KPP will continue to evaluate the value these products can deliver as more biosimilars continue to come to the market in an effort to drive the lowest net cost for our clients and members.


\$54b

in Savings Over the Next Decade¹

¹D. Lawson, Allen Rand Corp., 2019.

800.917.4926
www.kpp-rx.com

U.S. Healthcare Biosimilar Adoption Challenges




Channel Complexity

Biosimilars and biologics typically are covered on the medical benefit even though the drugs can be covered and administered on the pharmacy benefit - resulting in confusion and slow adoption.



Health Literacy


While biosimilars can be substituted for their biologic reference products, only a small number of biosimilars have been approved and designated as interchangeable with the reference product.



Pricing Competition


To protect market share, reference drug manufacturers adjust their prices downward to slow adoption of biosimilars.

Kroger Prescription Plans: Biosimilar 360 Plan



Engagement

We partner with medical benefit providers to identify opportunities for increased adoption facilitating data exchange and accurate reporting.



Collaboration

We connect prescribers and patients with our specialty pharmacy to help stakeholders understand the value of biosimilars and increase adoption.



Low Net Cost Strategy

We advocate in our clients' best interest by focusing on patient safety, clinical effectiveness, and highest value.

Exclusive Partnership with Kroger Specialty Pharmacy

Clinical Collaboration

generates robust policies with Specialty Rx

Personalized Treatment Plans

facilitates appropriate patient utilization

Innovative Formulary Management

drives higher adoption and cost savings

Remicade (infliximab)	⊗	→	⊙	Inflectra (infliximab-DYYB)
Neupogen (filgrastim)	⊗	→	⊙	Zarxio (filgrastim-SNDZ)
Neulasta (pegfilgrastim)	⊗	→	⊙	Ziextenzo (pegfilgrastim-BMEZ)
Procrit (epoetin alfa)	⊗	→	⊙	Retacrit (epoetin alfa-EPBX)
Lantus (insulin glargine)	⊗	→	⊙	Semglee (insulin glargine-YFGN)

Reference Biologic Product

Preferred Formulary Biosimilar

Conversion Results of Biosimilar Products

\$24k Biosimilar Savings Per Conversion²

²KPP 2021 Claims Utilization Data